Endologix (ELGX) Announces Presentation of Nellix EVAS System Post-Market Study Data in AAA Patients
- Wall St opens flat ahead of Easter break, eyes sharp Q1 gains
- Home Depot agrees to buy SRS Distribution, sees TAM expanding to $1 trillion
- Stocks head into quarter-end on the up; yen on intervention watch
- Dollar gains as inflation data looms; yen on intervention watch
- Piper Sandler: Stock rally likely to continue on rising recession risks
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
Leerink Partners Cuts Price Target on Endologix (ELGX) to $8 Following Analyst Day
November 18, 2016 7:20 AM ESTLeerink Partners maintained a Market Perform rating on Endologix (NASDAQ: ELGX), and cut the price target to $8.00 (from $11.00), following the company's analyst day. The focus of the presentation was around Nellix. There was news on Wednesday that potential approval has been pushed out ~6 months. This comes following a request for additional info from the FDA. Management also updated 2016 revenue... More
JPMorgan Downgrades Endologix (ELGX) to Neutral
November 16, 2016 10:11 AM ESTJPMorgan downgraded Endologix (NASDAQ: ELGX) from Overweight to Neutral with a price target of $10.00 (from $14.00).
For an analyst ratings summary and ratings history on Endologix click here. For more ratings news on Endologix click here.
Shares of Endologix closed at $9.84 yesterday.
... MoreEndologix (ELGX) will resume trading at 9:50am ET
November 16, 2016 9:22 AM ESTEndologix (NASDAQ: ELGX) will resume trading at 9:50am EST.
... MoreEndologix (ELGX) Announces FDA Request for Follow-up Data on EVAS-FORWARD IDE Study of Nellix EVAS System
November 16, 2016 9:02 AM ESTEndologix, Inc. (Nasdaq: ELGX) announced that the U.S Food and Drug Administration (FDA) has requested the Company provide 2-year patient follow-up data from the EVAS-FORWARD IDE Study of the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). The Company expects these data to be available and submitted to the FDA in the second quarter of 2017, followed by a possible FDA advisory panel meeting by the end of 2017, and potential FDA PMA approval of Nellix in the second quarter of... More
Endologix (ELGX) trading halted with news pending
November 16, 2016 8:55 AM ESTEndologix (NASDAQ: ELGX) trading halted with news pending.
... More